Cardiogen
One of the Khavinson "bioregulator" peptides from Russian aging research, marketed for the heart. Evidence comes mainly from Russian cell and animal studies.
Sold as a supplement in Russia; not approved in the US. Research use only.
Look it up on Wikipedia25 listings across 24 independently tested vendors, ranked by price per milligram after coupon codes anyone can use. Vendors you can only order from by message are hidden.
Some links here are affiliate links: if you buy through one, this site may earn a commission at no extra cost to you. Prices, rankings and plans are worked out the same way whether or not a vendor pays one.
Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it.
Daily price tracking started October 7, 2026; a price-history chart appears here once a few days have been collected.
| Vendor | Trust | Listing | Vials | Price | Per mg | |
|---|---|---|---|---|---|---|
Andy Peps Studio #64 by metascore · China |
CA20 Cardiogen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy | |
Baohua Dongnuo Biotechnology BHD #77 by metascore · China |
CA20 Cardiogen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy | |
LN Peptides #254 by metascore · China |
Metascore 71Finnrick 72%Bought vials 99% of label · 39 testsTitrateLabNo report for thisOnline checkout |
CA20 Cardiogen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy |
BeiBangAn #28 by metascore · China |
CA20 Cardiogen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy | |
Uther #62 by metascore · China |
Metascore 79Finnrick 64%Bought vials 105% of label · 73 testsTitrateLabNo report for thisOnline checkout |
Cardiogen 20mg (10 Vials / Kit) | 10 × 20 mg = 200 mg | $150.00 $15.00 per vial |
$0.750 | Buy |
Qingdao Sigma Chemical QSC #69 by metascore |
Cardiogen 20mg | 20-Vial Kit | AEDR Cardiac Bioregulator | Cardiomyocyte Gene Regulation Research | 20 × 20 mg = 400 mg | $450.00 $22.50 per vial |
$1.13 | Buy | |
Bulk Peptide Wholesale #29 by metascore |
Metascore 82 medium confidenceFinnrick 68%Bought vials 103% of label · 7 testsTitrateLab · PeptideBaseNo report for thisOnline checkout |
Cardiogen 20 mg (10 vials) | 10 × 20 mg = 200 mg | $250.00 $25.00 per vial |
$1.25 | Buy |
Qingdao Sigma Chemical QSC #69 by metascore |
Cardiogen 20mg | 10-Vial Kit | AEDR Cardiac Bioregulator | Cardiomyocyte Gene Regulation Research | 10 × 20 mg = 200 mg | $250.00 $25.00 per vial |
$1.25 | Buy | |
Ion Peptide #4 by metascore |
Metascore 87 medium confidenceFinnrick 82%Bought vials 108% of label · 4 testsTitrateLab · PeptideBase · Peptide CriticLab 99.7% pure · 108% of labelConfirmed with lab: 40 of 40Online checkout |
Cardiogen – 25mg | 1 × 25 mg | $44.25 | $1.77 | Buy |
Peptidology #5 by metascore · US, AZ 85254 |
Metascore 87Finnrick 71%Bought vials 97% of label · 18 testsTitrateLab · PeptideBase · Peptide Critic · PeptideCheckedNo report for thisConfirmed with lab: 34 of 34Online checkout |
Cardiogen 20 mg (20mg) | 1 × 20 mg | $43.99 | $2.20 | Buy |
Peptide Crafters #57 by metascore · US |
Metascore 79Finnrick 60%PepIndex 22/100Bought vials 111% of label · 59 testsTitrateLab · Peptide CriticNo report for thisConfirmed with lab: 26 of 26Online checkout |
CARDIOGEN (25mg) | 1 × 25 mg | $55.00 | $2.20 | Buy |
Amino Usa #136 by metascore · US |
Metascore 74 medium confidenceFinnrick 32%Bought vials 89% of label · 3 testsTitrateLabLab 99.8% pure · 99% of labelAccount needed |
Cardiogen 20mg | 1 × 20 mg | $50.00 | $2.50 | Buy |
Eros Peptides #129 by metascore · US, GA 30339 |
Metascore 74 medium confidenceFinnrick 77%Bought vials 110% of label · 3 testsTitrateLab · Peptide CriticLab report (image)Online checkout |
Cardiogen 20MG | 1 × 20 mg | $50.99 | $2.55 | Buy |
Pure Peptide Labs #53 by metascore · US |
Metascore 79 medium confidenceFinnrick 63%PepIndex 23/100Bought vials 102% of label · 4 testsTitrateLab · PeptideBase · Peptide CriticNo report for thisOnline checkout |
Cardiogen 20 mg | 1 × 20 mg | $54.95 | $2.75 | Buy |
Lab Rat Peptide #206 by metascore · US |
Cardiogen 20MG | 1 × 20 mg | $55.00 | $2.75 | Buy | |
Verified Peptides #120 by metascore · US: FL |
Metascore 75Finnrick 65%Bought vials 109% of label · 39 testsTitrateLab · PeptideBase · Peptide Critic · PeptideCheckedNo report for thisOnline checkout |
Cardiogen Peptide (20MG) | 1 × 20 mg | $55.00 | $2.75 | Buy |
Liberty Peptides #63 by metascore · US, DE 19801 |
Metascore 79Finnrick 53%Bought vials 107% of label · 18 testsTitrateLab · PeptideBaseLab 99.3% pure · 99% of labelOnline checkout |
Cardiogen (20mg) | 1 × 20 mg | $55.00 | $2.75 | Buy |
Amino Asylum #245 by metascore |
Metascore 71Finnrick 62%PepIndex 26/100Bought vials 100% of label · 15 testsTitrateLab · PeptideBaseNo report for thisOnline checkout |
Cardiogen 20MG | 1 × 20 mg | $64.99 | $3.25 | Buy |
Atomik Labz Affiliate #85 by metascore · US. Florida, 33411 |
Metascore 77Finnrick 69%Bought vials 112% of label · 44 testsTitrateLab · Peptide CriticNo report for thisOnline checkoutCheck vendor |
Cardiogen 20mg | 1 × 20 mg | $65.00 | $3.25 | Buy |
Biolongevity Labs #166 by metascore · US, Akron, OH 44321 |
Metascore 73Finnrick 71%PepIndex 58/100Bought vials 102% of label · 34 testsTitrateLab · Peptide CriticNo report for thisOnline checkout |
Cardiogen (20mg) | 1 × 20 mg | $69.97 | $3.50 | Buy |
Alpha BioMed #281 by metascore · US |
Cardiogen (20mg) | 1 × 20 mg | $72.00 | $3.60 | Buy | |
Core Peptides #282 by metascore |
Metascore 70 medium confidenceFinnrick 76%PepIndex 24/100Bought vials 92% of label · 4 testsTitrateLab · PeptideBase · Peptide Critic · PeptideCheckedLab 99.8% pureOnline checkout |
Cardiogen – 20MG | 1 × 20 mg | $75.00 | $3.75 | Buy |
Paramount Peptides #133 by metascore · US CA |
Metascore 74Finnrick 64%PepIndex 55/100Bought vials 114% of label · 65 testsTitrateLab · Peptide CriticNo report for thisOnline checkout |
Cardiogen (20mg) | 1 × 20 mg | $80.00 | $4.00 | Buy |
Certified Peptides #66 by metascore · US, WA 98579 |
Metascore 79Finnrick 58%Bought vials 100% of label · 12 testsTitrateLabNo report for thisOnline checkout |
CARDIOGEN 20 MG | 1 × 20 mg | $105.00 | $5.25 | Buy |
Aavant Research #2 by metascore · US |
Metascore 90Finnrick 86%Bought vials 103% of label · 24 testsTitrateLabNo report for thisOnline checkout |
Cardiogen 20ml | 10 × 20 ml | $125.00 $12.50 per vial |
– | Buy |
Mixing a 20 mg vial
What each common amount of bacteriostatic water gives you on a U-100 insulin syringe. Pick a vial size above to change it.
| Water | Strength | Per 10 units (0.1 mL) | Per unit |
|---|---|---|---|
| 1 mL | 20 mg/mL | 2,000 mcg | 200 mcg |
| 2 mL | 10 mg/mL | 1,000 mcg | 100 mcg |
| 3 mL | 6.667 mg/mL | 666.7 mcg | 66.67 mcg |
| 5 mL | 4 mg/mL | 400 mcg | 40 mcg |
Published lab results
5 certificates of analysis that vendors publish for Cardiogen. Numbers are only filled in where the document is readable text; image-only COAs are linked without numbers. A vendor's own COA shows one tested sample, not every batch.
| Vendor | Lab | Date | Label | Measured | Purity | Batch | |
|---|---|---|---|---|---|---|---|
Ion Peptide |
Freedom Diagnostics ✓ lab | 2026-09-05 | 25 mg | 26.95 mg 108% | 99.74% | CD25-09022026 | View |
Core Peptides |
Vanguard Laboratory | 2026-08-21 | 20 mg | – | 99.8% | C74114 | View |
Amino Usa |
BioRegen | 2026-06-29 | 20 mg | 19.72 mg 99% | 99.82% | 26CARD20-0005 | View |
Liberty Peptides |
– | 2026-02-18 | 20 mg | 19.85 mg 99% | 99.3% | LPUS2096 | View |
Eros PeptidesCOA note |
Janoshik | – | 20 mg | – | – | View (image) |
Doses studied in research Animal or lab studies only
What was given to people (or animals) in published studies and official labels, each linked to its source. This is not a recommendation: study products, purity and supervision differ from research-grade vials.
Animal studies: Only rat tissue-culture work (effective concentration reported as 0.05 ng/ml) and a rat tumour model with injections at unstated doses, all from one research group.
No human studies found; most PubMed hits for 'Cardiogen' refer to the unrelated CardioGen-82 imaging generator. Doses in animal studies do not translate directly to people.
What the research says
Searches for 'Cardiogen' mostly return CardioGen-82, an unrelated rubidium-82 PET generator. For the peptide cardiogen (Ala-Glu-Asp-Arg), evidence is a few rat tissue-culture and tumour-model papers from one Russian group (the St Petersburg Institute of Bioregulation and Gerontology), plus one small uncontrolled-looking Russian clinical report in 32 elderly patients that cannot support efficacy conclusions.
Key papers ✓ 3~ 1? 4
-
[The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats].Cells / labIn vitro tissue culture with 20 amino acids and cardiogen at 10(-12) M
In organotypic myocardial tissue culture from young and old rats, cardiogen stimulated cell proliferation in both ages and reduced p53 expression, interpreted as reduced apoptosis.
Key result7 of 20 amino acids stimulated proliferation in young rat tissue and only 2 in old rat tissue; cardiogen stimulated proliferation in both
Study details
- Studied
- Organotypic myocardial tissue explants from 3- and 24-month-old rats
- Compared with
- Control cultures
- Main outcome
- Cell proliferation and p53 expression (apoptosis)
- Authors' conclusion
- Cardiogen strongly stimulated proliferation in myocardial tissue from young and old rats and decreased p53 expression, which the authors suggest indicates inhibition of apoptosis.
- Limitations
- In vitro tissue explants; group sizes not stated.
-
[The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats].Cells / labOrganotypic tissue culture with cardiogen, bronchogen, prostamax and pancragen at 0.05 ng/ml
In organotypic cultures from young and old rats, cardiogen stimulated heart explant growth specifically, while other peptides acted on their own matching tissues.
Study details
- Studied
- Organotypic explants of heart, lung, prostate and pancreas from young (3-week) and aged (18-month) rats
- Compared with
- Control explants
- Main outcome
- Tissue-specific explant growth
- Authors' conclusion
- At 0.05 ng/ml each peptide stimulated growth in its matching tissue culture compared with controls, so the authors suggest the peptides could stimulate reparative processes in ageing tissues.
- Limitations
- Explant cultures only; no numerical data in the abstract.
-
Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats.Animalssize not reportedCardiogen injections in several dose groups vs control
In senescent rats with transplanted M-1 sarcoma, cardiogen injections dose-dependently slowed tumour growth via haemorrhagic necrosis and tumour-cell apoptosis, an anti-tumour rather than cardiac outcome.
Study details
- Studied
- Senescent rats with transplanted M-1 sarcoma
- Compared with
- Control
- Main outcome
- Tumor apoptosis and tumor growth
- Authors' conclusion
- Cardiogen dose-dependently inhibited M-1 sarcoma growth via hemorrhagic necrosis and increased tumor cell apoptosis, apparently acting through the tumor vascular network rather than by direct cytostatic effect.
- Limitations
- Rat transplant tumor model; group sizes not stated.
-
[Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging].Cells / labIn vitro study of peptides T-32, T-38 and cardiogen
In ageing human prostate fibroblast cultures, cardiogen and two other short peptides increased expression of differentiation signalling factors; the related peptide T-38 was most active.
Study details
- Studied
- Human prostate fibroblast cultures (young vs senescent)
- Compared with
- Control (young culture after 1 passage)
- Main outcome
- Expression of CXCL12, WEDC1 and ghrelin by confocal microscopy
- Authors' conclusion
- All the peptides enhanced expression of differentiation signaling factors reduced in senescent cultures; T-38 was the most active.
- Limitations
- In vitro; no quantitative data in the abstract.
-
Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.No new dataNarrative review
A review of senescence-associated secretion in cardiovascular cells proposes vasoprotective peptides as a target but reports no clinical trial evidence.
Study details
- Studied
- Cardiovascular system cells and senescence-associated secretory phenotype
- Authors' conclusion
- Vasoprotective peptides, including KED tripeptide and AEDR tetrapeptide, regulate molecules involved in inflammaging and SASP, indicating prospects for peptide-based drugs for age-associated cardiovascular pathology.
- Limitations
- Narrative review; no original data.
-
Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides.No new dataFluorescence quenching binding assays
Binding study showing Ala-Glu-Asp-Arg and related short peptides attach to specific histone sites; mechanistic only.
Study details
- Studied
- Short peptides and FITC-labeled wheat histones in vitro
- Main outcome
- Peptide binding to histones and histone-oligonucleotide complexes
- Authors' conclusion
- Short peptides including Lys-Glu-Asp-Gly bind wheat histones in a site-specific manner; the authors suggest this may be an epigenetic control mechanism in chromatin.
- Limitations
- Cell-free assay with plant histones; mechanistic suggestion only.
-
Влияние геропротекторных пептидов на экспрессию внутриядерных белков, регулирующих биосинтез рибосом в культуре опухолевых клетокCells / labIn vitro comparison of cardiogen and peptide T-32
In cultured tumour cells, cardiogen reduced expression of argyrophilic nucleolar-organizer proteins (ribosome biogenesis) while peptide T-32 raised it; mechanistic work from the developer's institute with no numbers in the abstract.
Study details
- Studied
- Tumour cell culture
- Main outcome
- Expression of argyrophilic proteins in nucleolar organizer regions
- Authors' conclusion
- Cardiogen decreased and T-32 stimulated expression of argyrophilic proteins of the nucleolar organizer region in tumour cells; the peptides act in opposite directions.
- Limitations
- Cell culture only; no quantitative data in the text available; developer's institute.
-
Роль пептидных биорегуляторов в повышении эффективности лечения больных в пожилом возрастеHumans32 peopleRandomized20 days of treatment, assessed at 2 weeksTwo-group comparison of standard therapy with or without peptide bioregulators; randomization and blinding not stated
In 32 elderly patients, adding cardiogen (12 patients with ischaemic heart disease, hypertension, heart failure; given with bronchogen in 5 COPD patients) to standard care was followed by more improvement (95% vs 73%) than standard care alone; small, unblinded-looking, no stated randomization, and cardiogen was not isolated from bronchogen overall.
Key resultPositive dynamics in 95% with peptide bioregulators vs 73% with standard therapy alone; subjective improvement after 1 week in 89% vs 67%
Study details
- Studied
- Elderly patients (mean age 76) with ischaemic heart disease, hypertension and heart failure, or COPD
- Compared with
- Standard treatment alone (15 patients)
- Main outcome
- Subjective improvement and ECG, blood pressure, spirometry and blood chemistry
- Sample
- 32 patients: 17 given peptide bioregulators (12 cardiogen, 5 bronchogen) and 15 controls
- Authors' conclusion
- The authors report marked effectiveness of cardiogen and bronchogen added to standard therapy, and no complications were observed.
- Limitations
- Very small, no stated randomization or blinding, no statistics given, mixed cardiogen/bronchogen group, outcome criteria loosely defined.
Reported side effects
Only one small Russian clinical report exists (no complications noted in 12 patients given cardiogen); papers about 'CardioGen-82' concern an unrelated PET radiopharmaceutical.
1 registered human trial (0 active)
✓ positive · ✗ negative · ~ mixed · ? inconclusive, judged on each paper's own main outcome. Grades: A strong human evidence → D little or none. Papers and verdicts are drawn from PubMed, Europe PMC and Russian journals (CyberLeninka); not medical advice.
Registered clinical trials 1 on ClinicalTrials.gov · 0 active · 1 completed
| Trial | Status | Phase | People | Sponsor |
|---|---|---|---|---|
| Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning NCT01424774 · started 2011-09 |
Completed | – | 155 | Bracco Diagnostics, Inc |
All 1 Cardiogen trials, with countries and summaries · Search ClinicalTrials.gov · Recruiting trials for every peptide
Discussions elsewhere
Experiences and questions about Cardiogen on other sites. Treat anecdotes with care.
Cardiogen: questions people ask
What is Cardiogen?
Russian short-peptide bioregulator. One of the Khavinson "bioregulator" peptides from Russian aging research, marketed for the heart. Evidence comes mainly from Russian cell and animal studies.
How much does Cardiogen cost?
The cheapest Cardiogen from an independently tested vendor is $0.475 per mg (Andy Peps Studio, CA20 Cardiogen 20mg * 10 vials, $95.00). Across 25 listings from 24 vendors the median is $2.55 per mg.
Where can I buy Cardiogen?
24 vendors tested by Finnrick sell Cardiogen. The cheapest per mg right now: Andy Peps Studio ($0.475), Baohua Dongnuo Biotechnology BHD ($0.475), LN Peptides ($0.475). 4 of them publish a lab report (COA) for Cardiogen; compare lab scores and reports in the table above before buying.
How much bacteriostatic water for 20 mg of Cardiogen?
Adding 2 mL of bacteriostatic water to a 20 mg vial of Cardiogen gives 10 mg/mL: each 10 units on a U-100 insulin syringe holds 1,000 mcg. With 1 mL it's 20 mg/mL (2,000 mcg per 10 units); with 3 mL, 6.667 mg/mL (666.7 mcg per 10 units). More water makes small amounts easier to measure. Mixing charts: 20 mg, 25 mg.
Is Cardiogen FDA approved?
Sold as a supplement in Russia; not approved in the US. Research use only.
Can Cardiogen be compounded in the US?
Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it. Compounding status for every peptide.
Does Cardiogen work? What does the research say?
Evidence grade C (mostly animal studies), from 8 papers: No controlled trials; one rat tumour study and one small non-randomized human report (cardiogen pooled with bronchogen), plus cell work from the developer's group. Searches for 'Cardiogen' mostly return CardioGen-82, an unrelated rubidium-82 PET generator. For the peptide cardiogen (Ala-Glu-Asp-Arg), evidence is a few rat tissue-culture and tumour-model papers from one Russian group (the St Petersburg Institute of Bioregulation and Gerontology), plus one small uncontrolled-looking Russian clinical report in 32 elderly patients that cannot support efficacy conclusions. See the papers.
Are there clinical trials of Cardiogen?
ClinicalTrials.gov lists 1 registered trials of Cardiogen: 0 active, 1 completed. Examples: Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning (Completed, 155 people).
What dose of Cardiogen was used in studies?
Cardiogen is tested only in animals or cells. Only rat tissue-culture work (effective concentration reported as 0.05 ng/ml) and a rat tumour model with injections at unstated doses, all from one research group. These are amounts used in published studies or official labels, not a recommendation.